Abu Serajuddin, Ph.D, joined St. John’s University in September 2008 as Professor of Industrial Pharmacy after working for 32 years in major multi-national pharmaceutical companies in scientific and managerial positions. In his latest positions in the industry, he worked for Novartis Pharmaceuticals Corp. as Director (1999-2002) and Executive Director (2002-2003) for drug product development in the US (Department Head, Pharmaceutical R&D) and then as Executive Director of Science, Technology & Outsourcing (2003-2008) with global responsibilities of developing drug delivery and pharmaceutical processing technologies and the management of science and technology initiatives (Head, Science & Technology Forum). Prior to joining Novartis, he worked in Pharmaceutical R&D in Bristol-Myers Squibb (1986-1999) and Revlon Health Care Group (1976-1986); the later became Sanofi-Aventis through mergers. Novartis named him Novartis Leading Scientist (2005) for extraordinary scientific excellence, and Bristol-Myers Squibb bestowed him President’s Award unprecedented 3 times (1996-1998) for outstanding contribution to drug development.
At St. John’s University, Dr. Serajuddin has built a world-class teaching and research program for development of drug delivery systems and pharmaceutical processing technologies. He helped the University in establishing the Industrial Pharmaceutical Innovation Laboratory for advanced research in pharmaceutical technologies. His contributions have been recognized by St. John’s with the Faculty Recognition Award for Outstanding Teaching and Services consecutively 10 times (2009-2018), College of Pharmacy and Health Sciences Distinguished Alumni Award (2018), and the University Medal for Outstanding Achievement (2019).
He authored over 100 research papers and book chapters, and he is a co-inventor in 13 issued patents. As of May 2019, his publications have received over 8000 citations in the pharmaceutical literature. He made 140 invited presentations in major scientific conferences and meetings in the USA and abroad (France, Croatia, Japan, China, and Taiwan).
For his scientific and professional achievements, Dr. Serajuddin was elected Fellow of American Association of Pharmaceutical Scientists (AAPS) and American Pharmacists Association (APhA). AAPS also bestowed him three of its most distinguished awards: AAPS Research Achievement Award for Formulation Design and Development (2010), AAPS Research Achievement Award for Manufacturing Science and Engineering (2014), and AAPS Lipid-Based Drug Delivery Outstanding Research Award (2015). He was the recipient of the IPEC Ralph Shangraw Memorial Award (2016), the highest scientific recognition given by the International Pharmaceutical Excipients Council (IPEC). He held numerous leadership positions in professional organizations. Currently, he serves in Editorial Advisory Boards of Journal of Pharmaceutical Sciences and Journal of Excipients and Food Chemicals.
The primary mission of the Industrial Pharmacy Program at St. John’s University is to educate and train students to address drug product development needs of pharmaceutical companies in the USA, the majority of which are located in the northeast region of the USA within 200 miles of the university. It is one of the only two such Industrial Pharmacy programs in the USA. To meet the industry needs and develop better drug products, Prof. Abu Serajuddin has built the Industrial Pharmacy Innovation Center at St. John’s University.
Industrial Pharmacy Innovation CenterFacilities and Equipment
Current research interests:
Dr. Serajuddin’s research has been supported by $1,150,000 research grants from pharmaceutical industry (ABITEC, Catalent, Hoffmann La Roche, Abon Lab, Latitude Pharma, Bristol-Myers Squibb and others) and $700,000 seed money and equipment grant from St. John’s University. In addition, he helped raise $500,000 from alumni and friends to build Industrial Pharmacy Innovation Laboratory.
Recently, Dr. Serajuddin received National Science Foundation Planning Grant (2018-19) under the IUCRC program for establishment of the NSF Center for Integrated Material Sciences and Engineering for Pharmaceutical Products (CIMSEPP), in collaboration with the University of Minnesota and New Jersey Institute of Technology (NJIT).
Publications (10 years; 2009-2019, as of May 2019)
Invited Presentations (5 years; 2014-2019, as of May 2019)